About Us | Vantage Biomedical Partners

Leadership

Meet the Founders

Dr. Arvind Ravinutala

Co-Founder & Chief Medical Officer

MD | CMO, Fruit Street | P&T Chair, Medical Director & APD, Adventist Health

As Chief Medical Officer at Fruit Street, Dr. Ravinutala leads clinical strategy and represents the company to investors, the ADA, CDC, and Medicare Advantage partners. As P&T Committee Chair at Adventist Health White Memorial, he leads the committee that decides which drugs and devices get adopted at the hospital. As Medical Director, he oversees clinical operations and quality initiatives across the department. As Associate Program Director for the Internal Medicine Residency, he trains resident physicians and watches firsthand how they evaluate and adopt new technology. He also serves on the Scientific Advisory Board of Spiro Medical, a $67M-funded company developing a first-of-its-kind Pulmonary Neuromodulation System for severe asthma, led by former Axonics COO Rinda Sama, who also serves as Vantage's Senior Advisor. This combination — C-suite leadership, formulary and device adoption decisions, clinical operations oversight, residency training, and active device advisory — is what makes every Vantage assessment different.

Connect

Aswini Ravinutala

Co-Founder & Chief Technology Officer

BS Biomedical Engineering, UC Irvine | MSE Quality, Reliability & Statistical Engineering, Arizona State University

Aswini has worked with the medical device companies Vantage now evaluates. At Axonics, she was part of the operations engineering team that navigated the regulatory and manufacturing path leading to Boston Scientific's $4.1B acquisition — working across design controls, manufacturing scale-up, and quality systems for Class II/III devices. At Vantage, she brings the engineering perspective to due diligence: assessing whether manufacturing processes can scale, whether quality systems will survive an FDA audit, and whether engineering teams have the depth to execute. Her areas of focus include manufacturing due diligence and supplier risk assessment, quality system compliance (ISO 13485, 21 CFR 820), design controls and V&V for Class II/III devices, regulatory pathway analysis (510(k), De Novo, PMA), and technical feasibility assessment for investors.

Connect

Assessment Coverage

Integrated MD + BME Evaluation

Every assessment combines clinical insight with engineering rigor, creating a unified risk intelligence that neither discipline alone can provide.

Clinical Assessment

Physician Leadership

Clinical Adoption Likelihood

Physician willingness to integrate

Physician Workflow Integration

Operational friction & usability

Regulatory Strategy Viability

FDA pathway clarity & feasibility

Reimbursement Pathway Analysis

Payer coverage & economics viability

Competitive Clinical Positioning

Market adoption vs. alternatives

Technical Assessment

Engineering Leadership

Manufacturing Scalability

Production readiness & scale-up

Design Controls & Quality Systems

FDA QSR compliance & maturity

Supply Chain Resilience

Sourcing risks & dependencies

IP & Freedom to Operate

Patent landscape & liability

Design-for-Manufacturing Readiness

DFM optimization & cost trajectory

Integrated

Vantage

Score

Senior Advisor

Specialist Leadership

Advisor

Rinda Sama

Senior Advisor, Medical Device Operations & Commercialization

Rinda brings C-suite operating experience from two successful Boston Scientific acquisitions. As COO of Axonics, he scaled operations from startup to the $4.1B acquisition. Previously, he led Vessix Vascular operations through its BSX acquisition. Now CEO of Spiro Medical and board member of UroMems, he provides perspective on what acquirers evaluate and what makes portfolio companies succeed post-acquisition. BME (USC) and MBA (UC Irvine).

His operational perspective on manufacturing scale-up, quality system maturity, and post-acquisition integration directly informs our assessment methodology — bringing C-suite operating experience that enhances every evaluation.

Deep Domain Expertise

Built-In Clinical & Engineering Depth

Every engagement is led by our MD + BME founding team with direct device commercialization experience, guided by C-suite advisory from Rinda Sama. For assessments requiring additional category-specific clinical depth, physician specialist consultation is available.

Orthopedic & Musculoskeletal

Cardiovascular & Electrophysiology

Neurology & Neuromodulation

Digital Health & SaMD

Surgical Instruments & Robotics

Wound Care & Regenerative Medicine

Respiratory & Pulmonary

Urology & Pelvic Health

150+

Physicians Informed by Our Work

Dr. Ravinutala serves as CMO at a digital health company, chairs the P&T Committee that decides device adoption at the hospital, is Medical Director overseeing clinical operations, is Associate Program Director for an Internal Medicine Residency, and sits on the SAB of a $67M neuromodulation company — bringing real-world adoption authority to every assessment

Documented Outcomes Database

Our proprietary analytical platform continuously refines pattern-matching accuracy

96%

Historical Risk Classification Accuracy

Our scoring framework correctly classified investment risk in validated analysis of documented medical device outcomes

Our Story

Why We Started Vantage

We saw the same pattern repeatedly: promising medical device companies failing not because of bad technology, but because of blind spots that specialized expertise could have identified early.

Investors were relying on generalist consultants who missed critical clinical adoption risks. Founders were getting regulatory advice that looked good on paper but fell apart in practice. The gap between technical due diligence and real-world medical device success was costing everyone.

Vantage was built to close that gap. By combining a physician's understanding of clinical reality with an engineer's rigor on technical execution, we provide insight that actually predicts outcomes. Most medical device failures follow predictable patterns — we're building the dataset to prove it.

Our Competitive Advantage

The Vantage Difference

Every Vantage assessment is led by both a physician and a biomedical engineer working in parallel — integrating clinical, regulatory, engineering, and commercial risk into a single report. Our proprietary methodology provides cross-category pattern matching that improves with every engagement.

2-3 wk

Typical turnaround — faster than traditional firms

3-4

Concurrent engagement capacity

Device categories assessed to date

Our Methodology

Our Proprietary Analysis Framework

Our proprietary analytical platform combines structured human assessment with pattern-matching against medical device outcomes curated from SEC filings, FDA records, clinical literature, and assessment engagements. Each engagement strengthens the model. The system is protected as trade secret intellectual property, continuously validated against real-world device performance, market adoption, and reimbursement outcomes across modalities.

See our full methodology →

The Vantage Team